

Images in Clinical Hematology

Diagnosis of indolent systemic mastocytosis in a patient with “seborrheic keratoses”



Habib Moshref Razavi ^{a,*}, Samuel Krikler ^b

^a Royal Columbian Hospital, New Westminster, BC, Canada

^b Surrey Memorial Hospital, Surrey, BC, Canada

ARTICLE INFO

Article history:

Received 15 April 2020

Accepted 24 October 2020

Available online 12 February 2021

A 52-year-old female patient is described. The patient was referred to a dermatologist with a two-year history of lesions on her head and neck. She was noted to have red brown, non-scaly, slightly infiltrative papules with a positive Darier's sign, which was biopsy proven to be cutaneous mastocytosis. Further workup showed a markedly elevated serum tryptase levels (58.9 micrograms/L). She denied any abdominal pain, diarrhea, flushing, severe allergic reactions or any other systemic symptoms. In order to rule out systemic mastocytosis a bone marrow biopsy was requested. The CBC and the peripheral smear were unremarkable. A dilute bone marrow aspirate showed normal trilinear hematopoiesis and no evidence of

increased myeloblasts or mast cells (Figure 1, panel A). A trephine biopsy showed nodular and paratrabecular mast cell lesions admixed with lymphocytes (Figure 1, panels B and C). Specifically both CD3+ T and CD20 + B-lymphocytes are admixed with the mast cell aggregates (Figure 1, panels D and E). CD34 showed no increase in myeloblasts (Figure 1, panel F). CD117 and tryptase confirmed large mast cell aggregates in the lesions seen on H&E (Figure 1, panels G–I). Quantitative PCR analysis identified the D816V mutation in the KIT gene and with no B or C symptoms the diagnosis of indolent systemic mastocytosis was reached.¹ The patient is periodically monitored with imaging, CBCs and serum tryptase levels.

* Corresponding author at: Fraser Health Authority, Division of Hematopathology and Transfusion Medicine, Department of Pathology and Laboratory Medicine, The Royal Columbian Hospital, 330 E Columbia St., New Westminster, BC, V3L 3W7, Canada.

E-mail address: habib.moshrefrazavi@fraserhealth.ca (H. Moshref Razavi).

<https://doi.org/10.1016/j.htct.2020.10.968>

2531-1379/© 2021 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).




Figure 1 – Bone marrow aspirate and trephine biopsy show the infiltration of a CD117 and tryptase positive mast cell infiltrate admixed with lymphocytes.

Conflicts of interest

The authors declare no conflicts of interest.

haematopoietic and lymphoid tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2017.

REFERENCE

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. World Health organization classification of tumours of